Global Implantable Glaucoma Device Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Implantable Glaucoma Device market size was valued at US$ 1363 million in 2024 and is forecast to a readjusted size of USD 3183 million by 2031 with a CAGR of 13.0% during review period.

A glaucoma drainage implant is a small device placed in the eye to treat glaucoma. There are many different ways to treat glaucoma. In addition to conventional and laser surgery, there are a variety of drugs to lower intraocular pressure (IOP). If these methods alone fail, doctors may suggest implants.

It is understood that glaucoma is an irreversible blinding eye disease that is highly harmful and irreversible. It is estimated that there are about 21.8 million glaucoma patients in my country. Glaucoma brings heavy economic burdens and physiological and psychological distress to patients and society.

Glaucoma blindness is a chronic process. Early detection and reasonable and effective treatment can avoid blindness. Lowering intraocular pressure to treat open-angle glaucoma (POAG) is currently the only proven effective method to delay the progression of glaucoma. For every 1 mmHg drop in intraocular pressure, the risk of glaucoma progression is reduced by 10%. The European, American and Asia-Pacific Glaucoma Associations and my country's glaucoma diagnosis and treatment guidelines all recommend the setting of target intraocular pressure. The main methods of treating glaucoma in my country include drugs, lasers and surgery. However, due to the complexity of risk factors, target intraocular pressure is not the same, and individual responsiveness to treatment varies. It has been reported that 1/3 of patients do not meet the target intraocular pressure, which means that they will find it difficult to maintain good vision and quality of life during their lifetime. Therefore, it is urgent to develop new methods to solve this problem. Internationally, new, minimally invasive, and biocompatible drainage devices provide more options and better solutions for glaucoma treatment.

On January 9, 2021, China's first Santian PRESERFLO drainage device implantation surgery was completed at the Boao Super Hospital in the Boao Lecheng Pilot Zone. The surgery was performed by Professor Zhang Shaodan of the International Eye and Optometry Center of the Boao Super Hospital and the Affiliated Eye and Optometry Hospital of Wenzhou Medical University. The successful completion of the surgery means that my country has achieved another major breakthrough in the field of glaucoma treatment, bringing new hope to the vast number of glaucoma patients in my country. PRESERFLO™ MICROSHUNT is an innovative glaucoma drainage device, which is a minimally invasive surgery for the treatment of glaucoma. Compared with traditional glaucoma filtration surgery, minimally invasive glaucoma surgery is considered to be less damaging, safer, and has a faster recovery after surgery while ensuring efficacy.

Market development trend

Technological innovation: With the continuous advancement of science and technology, implantable glaucoma devices will continue to introduce new technologies and new materials to improve product performance and safety. For example, the integration of intelligent technology will make glaucoma shunts more accurate and efficient.

Personalized treatment: With the improvement of medical standards and the diversification of patient needs, personalized treatment will become an important development direction of the implantable glaucoma device market. Enterprises need to provide customized products and services according to the specific conditions of patients to meet their personalized needs.

Internationalization strategy: With the development of global economic integration, the demand for implantable glaucoma devices in the international market is also increasing. Enterprises will strengthen international cooperation and expand overseas markets to achieve market expansion and global business layout.

This report is a detailed and comprehensive analysis for global Implantable Glaucoma Device market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Implantable Glaucoma Device market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Implantable Glaucoma Device market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Implantable Glaucoma Device market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Implantable Glaucoma Device market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Implantable Glaucoma Device

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Implantable Glaucoma Device market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Santen Pharmaceutical, Johnson and Johnson, Advanced Ophthalmic Innovations (AOI), New World Medical, Nova Eye Medical, Glaukos Corp, Alcon, iSTAR Medical, Henan Universe, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Implantable Glaucoma Device market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Trabecular Meshwork-Schlemm Canal Drainage
Subconjunctival Drainage
Others

Market segment by Application
Hospital
Ophthalmology Clinics
Others

Major players covered
AbbVie
Santen Pharmaceutical
Johnson and Johnson
Advanced Ophthalmic Innovations (AOI)
New World Medical
Nova Eye Medical
Glaukos Corp
Alcon
iSTAR Medical
Henan Universe
Ocular Therapeutix
PolyActiva
Health Guard Biomed

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Implantable Glaucoma Device product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Implantable Glaucoma Device, with price, sales quantity, revenue, and global market share of Implantable Glaucoma Device from 2020 to 2025.

Chapter 3, the Implantable Glaucoma Device competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Implantable Glaucoma Device breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Implantable Glaucoma Device market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Implantable Glaucoma Device.

Chapter 14 and 15, to describe Implantable Glaucoma Device sales channel, distributors, customers, research findings and conclusion.